New hope for Platinum-Resistant ovarian cancer: BL-B01D1 enters phase 3 trial

NCT ID NCT06994195

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 384 women with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatment. The goal is to see if BL-B01D1 can slow disease progression and improve survival. Participants receive either BL-B01D1 or one of three standard chemotherapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (a drug given by IV every 3 weeks)
What this could lead to: If it works, this could offer a new treatment option for women with ovarian cancer that no longer responds to platinum-based chemotherapy.
What could go wrong: This is an early Phase 3 trial, so results are not guaranteed. The drug may not work better than current chemotherapies and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube neoplasm ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CANCER PRIMARY PERITONEAL CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.